LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Randox Presents Acusera Smart Controls Range

By LabMedica International staff writers
Posted on 03 Feb 2025
Image: The Acusera Smart QC line comprises controls for clinical chemistry, immunoassay, liquid cardiac and PTH (Photo courtesy of Randox)
Image: The Acusera Smart QC line comprises controls for clinical chemistry, immunoassay, liquid cardiac and PTH (Photo courtesy of Randox)

Randox Laboratories (Crumlin, UK) is highlighting its new Acusera Smart range of true third-party quality controls (QCs) at Medlab Middle East 2025 that offer complete test menu consolidation for laboratory internal quality control (IQC).

With approximately 70% of clinical decisions based on laboratory test results, the results provided must be accurate and reliable to prevent potential misdiagnosis or inappropriate treatment. Randox offers high-quality material that can help streamline procedures, whilst saving time and money for laboratories of all sizes and budgets. Randox offers an extensive product offering comprising third-party QCs & calibrators, interlaboratory data management, external quality assessment, calibration verification, and molecular IQC and EQA for infectious disease testing. Specializing in consolidation, the Acusera range of multi-analyte controls is designed to reduce the number of individual controls required to cover a lab’s test menu, ultimately reducing costs, preparation time, and storage space.

At the 2025 edition of Medlab Middle East, Randox is highlighting its Acusera Smart controls range that is designed to fit directly onto a wide range of test systems without the need to aliquot material, thereby streamlining the QC process by minimizing human error and optimizing workflow. The Acusera Smart Controls range comprises controls for clinical chemistry, immunoassay, liquid cardiac, and PTH. The Acusera Smart PTH Control is intended for use with IVD assays for the quantitative determination of Parathyroid Hormone in human serum and plasma. The Acusera Smart Liquid Cardiac Control is designed to cover a range of cardiac markers at clinical decision levels, eliminating the need for additional low-level controls at extra expenses. It is intended for use with IVD assays for the quantitative determination of 7 cardiac markers. The Acusera Smart Liquid Chemistry Control is intended for IVD use in the QC of diagnostic assays. Three clinically significant levels are available. Covering 98 analytes, the control enables effective consolidation and cost savings. The Acusera Smart Liquid Immunoassay Control is intended for IVD use to cover immunoassay testing in a single tube. The three clinically significant levels provided not only ensure accurate performance at key decision levels but also eliminate the need for additional controls, enabling greater consolidation and cost savings.

Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more